SCHEMBL4725201

SCHEMBL4725201

Cc1nc2cccc(F)c2n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.44
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
PRMT5 O14744 1/20 0.40
DPP4 P27487 1/20 0.39
CYP11B2 P19099 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PARP1 P09874 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.37
PSMB8 P28062 1/20 0.37
HCRTR1 O43613 1/20 0.37
KCNK13 Q9HB14 2/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16806054 0.80 NPC1 (0.50) KDM4EALDH1A1LMNAPRMT5DPP4
SCHEMBL30893480 0.79 ALDH1A1 (0.44) PDE10AKDM4EALDH1A1MEN1KMT2A
SCHEMBL6118110 0.77 PRMT5 (0.47) KDM4EALDH1A1LMNAPRMT5DPP4
SCHEMBL21263258 0.77 PRMT5 (0.66) PDE10AKDM4EALDH1A1LMNAPRMT5
SCHEMBL22502924 0.77 ALDH1A1 (0.42) KDM4EALDH1A1LMNAPRMT5DPP4
SCHEMBL22894846 0.77 PDE10A (0.37) PDE10AKDM4EALDH1A1LMNAPRMT5
SCHEMBL12263309 0.77 MEN1 (0.47) PDE10AKDM4EALDH1A1PRMT5DPP4
SCHEMBL15840329 0.75 PARP1 (0.51) KDM4EALDH1A1LMNAMEN1KMT2A
SCHEMBL4725970 0.75 PDE10A (0.36) PDE10AKDM4EALDH1A1LMNAPRMT5
SCHEMBL29399807 0.71 CA1 (0.48) DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 EP disclosed
WO-2019157458-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2019-08-15 WO disclosed
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS EFREMOV IVAN 2008-11-13 US disclosed
WO-2008012623-A1 BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR PFIZER PRODUCTS INC. (US) 2008-01-31 WO disclosed
US-4782050-A BACTERICIDES PFIZER INC. (US) 1988-11-01 US disclosed
EP-0276942-A1 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof PFIZER INC. (US) 1988-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS PAICS, TMBIM6, ABCG2 PDE10A 93/4885KDM4E 2254/4885ALDH1A1 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.